|
| Reference | Patients | Serum ANGPTL2 (ng/ml) | ELISA kit | Conclusion of the study |
|
| [30] | Non-small-cell lung cancer, China | 8.4 ± 1.7 versus 4.9 ± 1.0 in controls | USCN Life Science Inc., China | High ANGPTL2 is a novel potential biomarker for diagnosis and prognosis of patients with non-small-cell lung cancer. |
| [32] | Breast cancer, Japan | ~4.0 versus 2.0 in controls | IBL, Japan | High ANGPTL2 in breast cancer patients could represent a potential marker of breast cancer metastasis. |
| [33] | Hepatocellular carcinoma, China | Values not given
(ANGPTL2 not increased in cancer patients) | Not mentioned | ANGPTL2 drives hepatocellular carcinoma metastasis. |
| [34] | Esophageal cancer, Japan | ~1.5 versus 0.8 in controls | IBL, Japan | High ANGPTL2 is a novel biomarker for diagnosis and prognosis of patients with esophageal cancer. |
| [40] | Colorectal cancer, Japan | ~1.5 versus 0.8 in controls | IBL, Japan | ANGPTL2 is a potential marker for diagnosis, early recurrence and prognosis in colorectal cancer patients. |
| [38] | Colorectal cancer, Japan | 1.9 (meta (+)) versus 1.5 (meta (−)) | IBL, Japan | ANGPTL2 improves preoperative detection of lymph node metastasis in colorectal cancer. |
| [39] | Gastric cancer, Japan | ~1.5 versus 0.8 in controls | IBL, Japan | High ANGPTL2 correlates with the metastatic properties of gastric cancer and could be a biomarker for early diagnosis and recurrence. |
| [41] | Colorectal cancer, Japan | ~3.5 versus 2.7 in controls | IBL, Japan | High ANGPTL2 could be a potential biomarker for early detection of colorectal cancer. |
| [42] | Gastric cancer, Japan | ~3.6 versus 2.7 in controls | IBL, Japan | High ANGPTL2 could be a potential biomarker for gastric cancer. |
|
